Orloff MS - Search Results

1

Utility of PTEN protein dosage in predicting for underlying germline PTEN mutations among patients presenting with thyroid cancer and Cowden-like phenotypes.

Ngeow J, He X, Mester JL, Lei J, Romigh T, Orloff MS, Milas M, Eng C. Ngeow J, et al. Among authors: orloff ms. J Clin Endocrinol Metab. 2012 Dec;97(12):E2320-7. doi: 10.1210/jc.2012-2944. Epub 2012 Oct 12. J Clin Endocrinol Metab. 2012. PMID: 23066114 Free PMC article.

2

Genetic and phenotypic heterogeneity in the PTEN hamartoma tumour syndrome.

Orloff MS, Eng C. Orloff MS, et al. Oncogene. 2008 Sep 18;27(41):5387-97. doi: 10.1038/onc.2008.237. Oncogene. 2008. PMID: 18794875 Review.

3

Differential regulation of PTEN expression by androgen receptor in prostate and breast cancers.

Wang Y, Romigh T, He X, Tan MH, Orloff MS, Silverman RH, Heston WD, Eng C. Wang Y, et al. Among authors: orloff ms. Oncogene. 2011 Oct 20;30(42):4327-38. doi: 10.1038/onc.2011.144. Epub 2011 May 2. Oncogene. 2011. PMID: 21532617

4

Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers.

Heald B, Mester J, Rybicki L, Orloff MS, Burke CA, Eng C. Heald B, et al. Among authors: orloff ms. Gastroenterology. 2010 Dec;139(6):1927-33. doi: 10.1053/j.gastro.2010.06.061. Epub 2010 Jun 27. Gastroenterology. 2010. PMID: 20600018 Free PMC article.

5

A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands.

Tan MH, Mester J, Peterson C, Yang Y, Chen JL, Rybicki LA, Milas K, Pederson H, Remzi B, Orloff MS, Eng C. Tan MH, et al. Among authors: orloff ms. Am J Hum Genet. 2011 Jan 7;88(1):42-56. doi: 10.1016/j.ajhg.2010.11.013. Epub 2010 Dec 30. Am J Hum Genet. 2011. PMID: 21194675 Free PMC article.

6

Germline SDHx variants modify breast and thyroid cancer risks in Cowden and Cowden-like syndrome via FAD/NAD-dependant destabilization of p53.

Ni Y, He X, Chen J, Moline J, Mester J, Orloff MS, Ringel MD, Eng C. Ni Y, et al. Among authors: orloff ms. Hum Mol Genet. 2012 Jan 15;21(2):300-10. doi: 10.1093/hmg/ddr459. Epub 2011 Oct 6. Hum Mol Genet. 2012. PMID: 21979946 Free PMC article.

7

Lifetime cancer risks in individuals with germline PTEN mutations.

Tan MH, Mester JL, Ngeow J, Rybicki LA, Orloff MS, Eng C. Tan MH, et al. Among authors: orloff ms. Clin Cancer Res. 2012 Jan 15;18(2):400-7. doi: 10.1158/1078-0432.CCR-11-2283. Clin Cancer Res. 2012. PMID: 22252256 Free PMC article.

8

Germline PIK3CA and AKT1 mutations in Cowden and Cowden-like syndromes.

Orloff MS, He X, Peterson C, Chen F, Chen JL, Mester JL, Eng C. Orloff MS, et al. Am J Hum Genet. 2013 Jan 10;92(1):76-80. doi: 10.1016/j.ajhg.2012.10.021. Epub 2012 Dec 13. Am J Hum Genet. 2013. PMID: 23246288 Free PMC article.

9

Prevalence of germline PTEN, BMPR1A, SMAD4, STK11, and ENG mutations in patients with moderate-load colorectal polyps.

Ngeow J, Heald B, Rybicki LA, Orloff MS, Chen JL, Liu X, Yerian L, Willis J, Lehtonen HJ, Lehtonen R, Mester JL, Moline J, Burke CA, Church J, Aaltonen LA, Eng C. Ngeow J, et al. Among authors: orloff ms. Gastroenterology. 2013 Jun;144(7):1402-9, 1409.e1-5. doi: 10.1053/j.gastro.2013.02.001. Epub 2013 Feb 8. Gastroenterology. 2013. PMID: 23399955 Free PMC article.

10

Resveratrol enhances the anti-tumor activity of the mTOR inhibitor rapamycin in multiple breast cancer cell lines mainly by suppressing rapamycin-induced AKT signaling.

He X, Wang Y, Zhu J, Orloff M, Eng C. He X, et al. Cancer Lett. 2011 Feb 28;301(2):168-76. doi: 10.1016/j.canlet.2010.11.012. Epub 2010 Dec 17. Cancer Lett. 2011. PMID: 21168265

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

118 results

Search Page

Filters